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Deletions of the COL4A5 gene in patients with Alport syndrome.
Mutations in the COL4A5 gene encoding the a5 chain of type IV
collagen have been found in linkage with X-chromosomal Alport
syndrome (AS). To identify COL4A5 mutations in patients from Ger-
many with clinically defined AS, DNA from 20 unrelated patients was
analyzed by conventional Southern blotting. By using full length a5(IV)
cDNA probes, large COL4A5 deletions could be detected in two
patients. In one case, a 34 kb deletion affecting the 14 most 3' exons of
the gene was observed. The second patient harbored a complete
COL4AS deletion. In both cases, functional a5(IV) mRNA was unlikely
to be present. Clinically, both patients developed end-stage renal failure
before age 30. Furthermore, they had characteristic retinal flecks, and
sensorineural hearing loss with typical changes on the audiogram. The
patient with the complete deletion of COL4A5 lost the renal allograft
due to an anti-GBM mediated glomerulonephritis.
Familial hematuric renal disease in association with sensori-
neural deafness was first described by Alport in 1927 [11.
Anterior lenticonus and abnormal retinal pigmentation (fundus
albipunctatus) were recognized later as less common clinical
features of Alport syndrome [2—4]. At the ultrastructural level,
electron microscopic studies revealed characteristic defects in
Alport glomerular basement membrane (GBM) such as com-
bined thickening and thinning with splitting of the lamina densa
[5—8]. An altered antigenic composition of Alport GBM was
suspected early based on the observation of a reduced or absent
binding of anti-GBM antibodies from Goodpasture sera 19—11].
Subsequent studies added substantial evidence that Alport
syndrome is a type IV collagen disease [12, 13]. Genetically,
Alport syndrome proved to be heterogeneous [14—161. In the
majority of kindreds, however, transmission is compatible with
dominant X-linked inheritance [17, 181. Genetic linkage analy-
ses using anonymous DNA markers coherently identified an
Alport locus at the X chromosomal region q21.3-22 [19—21].
However, until recently only autosomal genes for type IV
collagen a chains had been identified. The genes for the main
constituents of type IV collagen, the al(IV) and a2(IV) chain,
have been mapped to chromosome 13, and the genes for the
novel chains a3 (IV) and a4(IV) have been localized to chro-
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mosome 2 [Reeders ST, personal communication, 1991, 22—24].
Recently, the cDNA for a previously unknown a5(IV) chain
was cloned. The corresponding gene (COL4A5) was subse-
quently mapped to the previously identified Alport locus on the
X-chromosome. Thus, a candidate disease gene for Alport
syndrome was identified [25, 26]. Subsequent analysis of
COL4A5 in 18 Alport kindreds from Utah led to the identifica-
tion of two different deletions and one point mutation [271. In
the large kindred harboring the point mutation, its segregation
in complete linkage with the presence or absence of the Alport
phenotype could be shown [27, 28].
The present study reports on the results of Southern blot
analysis of COL4A5 in 20 Alport kindreds from Germany. Two
new COL4A5 deletions were identified, both of which were
associated with the clinical phenotype of Alport syndrome in a
typical symptomatic constellation.
Methods
Patients
Patients from 20 unrelated families were studied (Table 1).
The clinical diagnosis was based on the presence of renal
insufficiency with hematuria, in association with two of the
following additional criteria: family history of renal insuffi-
ciency with hematuria, sensorineural hearing loss, anterior
lenticonus, and perimacular retinal flecks, respectively. Hema-
tuna was present in all patients included in this study. Mild to
moderate proteinuria was present in 17 of 20 (85%) patients.
Hearing loss occurred in 18 of 20(90%) patients, whereas ocular
lesions were present only inS of 20(25%). Electron microscopic
biopsy studies and/or the occurrence of post-transplant anti-
GBM antibodies assured the diagnosis in 10 cases. The mean
age of end-stage renal disease (ESRD) for juvenile Alport
syndrome was 19 years (range 14 to 27 years). For adult Alport
syndrome, it was 44 years (range 39 to 49 years). Thirteen out
of twenty patients had a family history of renal disease. Six
recorded pedigrees were clearly compatible with X-linked dis-
ease. A further seven pedigrees followed a dominant pattern of
inheritance, but were uninformative for X-linkage since there
were no offspring from affected males.
The pedigrees of the two patients with detectable COL4A5
deletions are shown in Figure 1. In kindred 902, the family
history is positive for hematuric renal disease. Subject 111-3 is a
62-year-old male who is clinically healthy. In subject 111-2,
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Table 1. Clinical data from 20 German Alport patients
ESRD
# Kindred HU PU HL OL Bx Tx GBM Ab age FH PD Type
1 A-9125 + + + RF nd 1 + 21 — d,u II
2 A-9129 + + + — LM 1 — 39 + d,X III
3 A-9128 + + + — EM — — 18 + d,u I
4 A-9124 + + + LA LM 1 — 17 + d,X II
5 A-902 + + + RF nd — — 26 + d,X II
6 A-901 + + + — EM 2 + 23 — d,u I
7 A-913 + + + — EM 1 + 16 — d,u I
8 A-919 + + — — LM — — (RI, 30 yrs) + d,u I
9 A-9114 + + + — nd — — 24 + d,X II
10 A-9132 + + + — EM — — 26 — d,u I
11 A-9133 + + + RF EM 1 + 20 — d,u I
12 A-9137 + + + LA nd 1 — 14 — d,u I
13 A-914 + — + — nd — — 27 — d,u I
14 A-915 -i- — -i- — LM — — 16 + d,u I
15 A-918 + + + — nd — — 49 + d,X III
16 A-9130 + + -- — EM 2 + 18 + d,u I
17 A-9131 + + + — EM I — 19 + d,u I
18 A-9134 + + — — EM I — 43 + d,u IV
19 A-9116 + + — — nd — — 24 + d,u ?
20 A-9136 + — + — EM — — (RI, 26 yrs) — d,u I
Abbreviations are: HU, hematuria; PU, proteinuria; HL, hearing loss; OL, ocular lesion; RF, retinal flecks; LA, lenticonus anterior; Bx, biopsy;
EM, electrom microscopy; LM, light microscopy; nd, not done; Tx, renal transplantation; GBM Ab, anti-GBM antibodies; ESRD, end-stage renal
disease; RI, renal insufficiency; FH, family history for renal disease; PD, pedigree; d, dominant; u, uninformative whether X-linked or autosomal;
X, X-linked. The classification of the type of Alport syndrome was done according to the criteria of Atkin et al [161: I, juvenile type (ESRD age
below 31), dominant uninformative whether X-linked or autosomal; II, juvenile type, dominant X-linked; III, adult type, X-linked dominant; IV,
adult type, purely renal disease, X-linked dominant.
death occurred due to renal failure at the age of 12. Ill-i is
asymptomatic except for microhematuria demonstrable by re-
peatedly positive urine analyses. In patient 11-2, hearing loss
became overt at age 9, requiring a hearing aid at the age of 10.
Audiometry at age 22 revealed a cochlear hearing loss of 60 dB
at lower, and 100 dB at higher tones. High blood pressure,
hematuria, and proteinuria were noticed incidently at age 23.
However, further medical evaluation and treatment was refused
by the patient. End-stage renal failure required hospitalization
at age 26, and chronic ambulatory peritoneal dialysis (CAPD)
was initiated. No renal biopsy was taken. Fundoscopy revealed
the presence of perimacular retinal flecks. Thus, the diagnosis
of Alport syndrome was made. In kindred 9125, family history
for renal disease and deafness was negative. Evaluation of
subjects 111-2, 11-I, 11-2, and I-I for hematuria was negative,
suggesting that the disease in patient 11-3 might be due to a de
novo mutation. In patient 11-3, hematuria and proteinuria were
first noticed at age 2, when an open ductus arteriosus Botalli
was obliterated surgically. Subsequent follow-up evaluations
until the age of 6 revealed persistent microhematuria with
episodes of macrohematuria. However, no biopsy was taken,
and the patient escaped from nephrological surveillance. At the
age of 12 he required a hearing aid. Audiometry demonstrated a
cochlear hearing loss of 50 dB at lower, and 60 dB at higher
tones. End-stage renal failure developed at the age of 21.
Fundoscopic evaluation revealed midperipheral retinal flecks,
and the diagnosis of Alport syndrome was made. At the age of
22, the patient received a renal allograft. Six months after
transplantation, serum tests for anti-GBM antibodies became
positive. Subsequently, transplant failure due to anti-GBM
nephritis developed. The graft was explanted 23 months after
transplantation.
DNA analysis
Genomic DNA was extracted from peripheral blood leuko-
cytes taken from 20 ml blood samples according to the method
described by Kunkel et al [291. Extracted DNA (7.5 g) was
digested over night with EcoRI, PstI, and TaqI restriction
enzymes and then separated by electrophoresis on horizontal
agarose gels (0.8%). The separated DNA fragments were sub-
sequently transferred to uncharged nylon membranes (Gene-
Screen; DuPont, Frankfurt, Germany) by Southern blotting
[30].
The five cDNA probes spanning the entire a5(IV) mRNA
used were JZ-4, HT14, PL31, MD6, and PC4b [25, 31]. They are
shown in Figure 2. The probes were labeled with 32P-dCTP
using a random hexanucleotide-primed reaction (Gibco BRL,
Eggenstein, Germany). Prehybridization and hybridization was
performed in rapid hybridization buffer (Amersham-Buchler,
Braunschweig, Germany) at 65°C for 2 and 18 hours, respec-
tively. Denatured radiolabeled probes were added to the hy-
bridization buffer in a final concentration of 2 x 106 cpm/ml.
Washing and autoradiography was done according to standard
protocols.
To verify the presence or absence of specific exons in the
affected males of kindred 902 and 9125, the polymerase chain
reaction (PCR) was used to amplify COL4A5 exons 14 and 15
from patient and control genomic DNA (the numbering of
COL4A5 exons throughout the current paper will be according
to reference 32). The chosen l8mer oligonucleotide primers
were: 14A, 5'-GTAAGfl'TGAArFGTAGC; 14 B, 5'-GrI'CA-
CAGCTGAACATGA; 15A, 5 '-GGTGAGCCTGGTCTGCCT;
15B, 5'-CTGGGAATCCAGGAAGGC. In a reaction volume of
50 jil, 25 ng of genomic template DNA was subjected to 26
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Fig. 1. Pedigrees of the two kindreds with COL4A5 deletions.
ct5(IV) Collagen (1685 aa)
NH2
Tripel helix NC1
COOH
JZ4 HT14 PL31
Fig. 2. Alignment of a5(IV) collagen protein chain (top), cv.5(IV) mRNA (middle), and a5(IV) cDNA probes (bottom). The names of the cDNA
clones are indicated next to the respective molecule. NH2, amino terminus; COOH, carboxy terminus; NC1, non-collageneous domain 1; 5',
capped mRNA end; TAA, translational stop codon; AAAAA, poly (A) tail.
cycles of amplification using TaqI polymerase and buffer from a
PCR kit (Perkin-Elmer/Cetus, Munich, Germany). The reaction
mixtures were separated by electrophoresis on horizontal aga-
rose gel (2.0%), and checked for the presence or absence of the
specific product.
Molecular detection of carriers in kindreds 902 and 9125 was
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done by slot blot analysis. Equal amounts of denatured genomic
DNA (6 g) from patients, possible carriers, and healthy donors
were filtered onto uncharged nylon membranes by using a slot
blot apparatus (Schleicher & Schuell, Heidelberg, Germany).
The filter was initially hybridized with the cDNA probe MD6.
This probe corresponds to a COL4A5 region that is deleted in
the two patients from kindreds 902 and 9125 (Fig. 4). For
control, the filter was rehybridized with an autosomal probe
specific for COL4A1. The ratio of the COL4A5/COL4A1 hy-
bridization signal intensities as obtained by laser densitometry
(Pharmacia, Freiburg, Germany) was calculated. The ratio
reflects the number of undeleted COL4A5 copies present in the
genome and therefore allows the detection of carriers (0.0, no
copy, =0.5, one copy, and =l.0, two copies).
Results
Genomic DNA analysis
By using three enzymes, no restriction fragment length
polymorphisms were detected in the 20 patients. In addition,
DNA samples from five healthy controls proved to be normal.
However, in two affected males from kindred 902 and 9125,
respectively, major structural abnormalities of COL4A5 were
revealed by the absence of bands after EcoRI, PstI, and TaqI
digestion (Fig. 3). DNA from patient 11-3 of kindred 9125 did not
show any COL4A5 specific hybridization signal with pooled or
single probes (Fig. 3A, lane 2; Fig. 3B lane 1). The concordant
absence of all fragments observed with different restriction
enzymes indicated a complete deletion of the COL4A5 exons.
The deletion breakpoints must be external to the most 3' and 5'
COL4A5 exons that are recognized by the cDNA probes JZ-4
and PC4b, respectively. The second affected individual, 11-2
from kindred 902, showed the absence of 6.6 and 1.4 kb EcoRI
bands (Fig. 3A, lane 6). One EcoRI band (7.5 kb) showed a
decreased signal intensity. The patient was also missing 2.2,
4.9, 5.5, and 16 kb PstI bands, and 1.6, 2.8 and 9.4 kb TaqI
bands (Fig. 3B, lane 3). This hybridization pattern indicated a
deletion of the 3' end of the gene (Fig. 4). To further charac-
terize the deletion in this patient, EcoRI digested genomic DNA
was subsequently hybridized to single cDNA probes. No hy-
bridization signal was obtained with the two most 3' terminal
cDNA probes PC4b and MD6 (data not shown; probe specific-
ity is in Fig. 4). Therefore, exons 1 through 11 must be deleted.
Upon hybridization with probe PL3 1, only 4 EcoRl bands were
detectable (0.4, 1.4, 2.7, and 4.8 kb; Fig. 3C) corresponding to
COL4A5 exons 15 to 19. Since no fragment of variant length
was detectable after EcoRI digestion, the deletion breakpoint
was concluded to be downstream of the EcoRI site in intron 14.
To verify the absence or presence of the exons of this COL4A5
region, exons 14 and 15 were PCR-amplified from genomic
DNA. Specific products were obtained for exon 15, but not for
exon 14 (Fig. 3D). This observation indicates that the intragenic
deletion breakpoint must be localized upstream of exon 14 (Fig.
4).
To address the question whether females in the two affected
kindreds were carriers or not, a semi-quantitative DNA slot blot
analysis was performed. Laser densitometry of the hybridiza-
tion signals permitted this analysis to discriminate between the
presence of only one or two copies per genome of certain
COL4A5 regions. The ratio of the signals obtained after hybrid-
ization with a COL4AS specific probe (MD6), and a COL4A1
specific probe, was 0.5 for the patient's mother (111-1) in
kindred 902 (Fig. 5). In contrast, for the patient's sister (902,
11-4), the ratio was 1.3, comparable to that for the normal
female control (Fig. 5). This observation indicated with some
certainty that the patient's mother, but not his sister was carrier
of the deletion. In kindred 9125, the ratio for the patient's
mother (111-2) was 1.2. The value was identical to that of the
normal female control, making a carrier status very unlikely
(Fig. 5).
Discussion
COL4A5 has recently been identified as the relevant gene for
X-linked Alport syndrome [25—27, 321. The gene encodes the aS
chain of type IV collagen. Using a5(IV) full length cDNA
probes with conventional Southern blots, we found COL4A5
deletions in 2 out of 20 non-related Alport patients. The
detection of COL4A5 deletions at a rate of 10% in this study is
consistent with the findings of other groups [27, 3 3—37] and may
probably represent a gene- and disease-specific feature. Until
now, several intragenic deletions of different sizes, affecting
different parts of COL4A5 have been identified in patients with
Alport syndrome. Less frequently, deletions with extragenic
breakpoints have been found. A complete gene deletion has
also been described by Antignac et al [331. In addition, a few
single base changes in various COL4A5 domains have been
identified [28, 31, 33, 35—38].
The deletions characterized in this manuscript have not been
previously identified in the affected kindreds. One deletion is a
whole gene deletion which obviously results in the complete
lack of the a5(IV) collagen protein (Fig. 4). The second deletion
affects about 34 kb from the 3' end of COL4A5, eliminating
exons 1 through 14. In this deletion, the coding sequence for
approximately 480 amino acid residues of the triple helical
domain, and for all of the 229 residues of the non-collagenous
(NC 1) domain of the a5(IV) chain is missing. Furthermore, the
sequence coding for the 3' untranslated region (UTR) of the
mRNA is also deleted (Fig. 4). Normal polyadenylation of
COL4A5 primary transcripts is unlikely to occur, since it is
critically dependent on the presence of signal sequences in the
3' UTR. In this case, processing of precursor nuclear RNA
leading to mature mRNA is likely to be blocked [39]. Therefore,
both deletions described here would probably lead to the
complete absence of the a5(IV) chain from the collagen IV
network of the basement membrane. It remains unresolved,
however, why the absence or structural alteration of a5(IV)
leads to progressive disruption of the GBM structure as ob-
served in Alport syndrome. Recently, it has been suggested that
the a5(IV) chain might be necessary for the correct incorpora-
tion of another novel chain, a3(IV), into the collagen IV
network of the basement membrane [23, 40, 41]. The lack of the
a5(IV) chain would thus affect the stability of the supramolec-
ular network of collagen IV [42].
The detection of female deletion carriers in the two affected
kindreds was hampered by the absence of variant bands upon
Southern analysis. The detection of the heterozygous loss of
COL4A5 or parts of it therefore required quantitative DNA
analysis. We addressed this problem by performing slot blot
analysis of DNA from questionable carriers, patients, and
healthy controls. The filters were hybridized with a probe
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Fig. 3. Genomic Southern blots of DNA from Alport patients and controls. (A) Panels of control (lane 1) and patient DNA (lanes 2—11,
corresponding to numbers ito lOin Table I) were digested with EcoRI and probed with pooled eDNA clones JZ4, HT14, PL31, MD6, and PC4b.
In all lanes a normal fragment pattern is shown, except for lanes 2 and 6. Lanes 2 and 6 correspond to subject 11-3 from kindred 9125, and subject
11-2 from kindred 902, respectively. (B) Southern analysis of PstI (left) and TaqI (right) digested DNA by using pooled eDNA probes. DNA of
affected males from kindred 9125 (lanes 1) and 902 (lanes 3) was compared with control DNA (lanes 2 and 4, respectively). No hybridization is seen
in the patient from kindred 9125. (C) Hybridization of EcoRI digested genomic DNA from subject 11-2 from kindred 902, and control DNA with
PL3I. PL31 recognizes exons 3-19. Of the normal 7 bands seen in the control, only four are present in the patient, corresponding to exons 15 to
19. (D) Agarose gel analysis of exon 14 and 15 PCR products from two Alport patients and one control. M, DNA size marker, lanes I and 4, product
from subject II-2/A-902, lanes 2 and 5, product from subject II-3/A-9i25, and lanes 3 and 6, product from control DNA. The absence of a specific
band denotes the absence of the respective exon in the template DNA. The lower band in lanes 4 to 6 represents a PCR artifact, possibly due to
primer dimerization. The upper band of approximately 130 bp is the exon 15-specific PCR product.
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(MD6) that specifically hybridizes to the COL4A5 region af-
fected in both kindreds, 902 and 9125. The results showed that
only the patient's mother in kindred 902 (111-1/902) is heterozy-
gous for a deletion at the COL4A5 locus. No heterozygosity
could be shown for the patient's mother in kindred 9125
(111-2/9125). These results are in agreement with the clinical
evaluation, where hematuria as the most consistent disease
marker for Alport syndrome [16] was demonstrated to be
present in subject 111-1/902, but not 111-2/9125. In conclusion,
there is strong evidence that the COL4A5 deletion detected in
the patient of kindred 9125 occurred as a de novo mutation.
Clinically, the two affected males from kindreds 902, and
9125 represent Alport patients with a typical symptomatic
constellation, that is, renal disease with hematuria, end-stage
renal failure before the age of 30, deafness, and ocular lesions.
No other associated symptoms have been observed; in partic-
ular there was no esophageal leiomyomatosis, which has been
described to occur in some cases in association with Alport
syndrome [33]. Some evidence has been reported that the
absence of the a5(IV) chain or the a5(IV) NC! domain from the
basement membrane may be associated with an increased risk
for the development of post-transplant anti-GBM disease in
Alport patients [36]. One out of five Alport patients with
post-transplant anti-GBM disease in this survey had a COL4A5
deletion (11-3/9125). In the other case with a COL4AS deletion
(11-2/902), a renal transplantation was not performed until now.
It may be possible that the elimination of critical epitopes from
the NC! domain of the a5(IV) chain or the failure to incorporate
the c3(IV) chain prevents the establishment of immunological
tolerance and thereby predisposes to the development of post-
transplant anti-GBM disease. To add substantial evidence to
this hypothesis, however, a greater number of cases have to be
investigated.
The clinical appearance of the two patients with detectable
deletions did not vary significantly from those apparently nor-
mal by Southern analysis. In analogy to other X-linked diseases
that have been characterized by gene analysis, for example,
hemophilia A [43], it seems likely that various types of minor
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Fig. 4. cDNA probe spec/1city, COL4A5 exon intron structure, EcoRI partial restriction map, and alignment of deletions. Top, squares labeled
JZ4, HT14, PL31, MD6, and PC4b represent the eDNA probes from Fig. 2. Upper middle, hatched boxes indicate exon regions of COL4A5,
numbered from the 3' end. The total number of exons is 51. The specificity of the eDNA probes is shown by the filling pattern. Exon 15 was cloned
by PCR. The adjacent intron sequences were not known at the time of the study, which is indicated by the open ovals. Lower middle, the position
of EcoRI restriction sites in the 3' half of COL4A5 is indicated by short vertical lines. The lengths, in thousand bases, of EcoRI restriction
fragments is shown beneath. Bottom, the extension of the deletions in kindreds 902, and 9125 is shown by the hatched bars.
COL4A5probe
COL4A 1 probe
Fig. 5. Slot blot analysis of genomic DNA for carrier detection. Equal amounts of denatured genomic DNA were transferred to a Nylon membrane
and initially hybridized with a probe specific for COL4A5 exons ito 11 (MD6). These exons are deleted in affected males of kindreds 902 and 9125.
For control, the blot was rehybridjzed with an autosomal probe specific for COL4A 1. Partial pedigrees of the two affected families are shown above
the slot blots. The ratio of the COL4A5/COL4AJ signal intensity as obtained by laser densitometry is shown below the slot blots. Comparison of
the intensity ratios allows the identification of the patient's mother in kindred 902 as deletion carrier. The patient's sister in kindred 902, and the
mother in kindred 9125 both show a normal hybridization signal indicating homozygosity. DNA from affected males does not hybridize to probe
MD6.
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COL4A5 mutations may be causative for the Alport phenotype.
Only some of them may be detectable by Southern analysis. In
the 18 patients that appeared to be normal by Southern blot in
this study, point mutations, frame shift mutations, and muta-
tions in promoter or locus-activating regions might yet be
present. Point mutations may affect exon sequences, splice
junctions, or intervening intron sequences and may cause
severe alteration of the gene product. Frame shift mutations
occur in exon sequences due to the insertion or deletion of one
or two nucleotides or multiples thereof. Promoter mutations
which affect the gene transcription rate are usually outside the
region covered by cDNA probes and may therefore not be
detectable by techniques using these probes. To evaluate the
prevalence and importance of these mutations in Alport syn-
drome, further studies using the appropriate methods that are
able to detect point mutations and small deletions/insertions are
currently undertaken by our group.
The present study illustrates that deletions of the COL4A5
gene are demonstrable only in a small number of families with
Alport syndrome. New strategies have to be developed that
allow the identification of small mutations which might be
responsible for the majority of Alport cases. In addition, Alport
syndrome might be more frequent than originally suspected. In
these cases of de novo mutations, molecular genetics may
provide a valuable diagnostic tool.
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